EORTC-30072-GUCG

A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
Study documentation
Trial StatusClosed for recruitment
DatesDate of activation: 23-Mar-09
Closed on : 12-Apr-13
Data management at EORTCMailbox
Phase3
Randomized trialYes
TypeAdjuvant
Targeted Sample sizeEORTC Groups: 200 - All Groups: 1656
Number of steps1
DrugSorafenib
Study Staff
Type of cancer
Participating Groups
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00492258
EudraCT2006-006079-19